干扰素联合胸腺肽α1序贯治疗对耐核苷类药物乙肝肝硬化患者病毒复制及肝纤维化的影响

摘要

[ABSTRACT]Objective:To analyze the effects of sequential therapy of interferon and thymosinα1 on virus replication and liver fibrosis in patients with nucleoside drugs-resistant hepatitis B cirrhosis.Methods:A total of 86 patients with hepatitis B cirrhosis were the research subjects and divided into observation group and control group (n =43)according to random number table,control group received interferon therapy alone,observation group received sequential therapy of interferon and thymosinα1,and then difference in virus replication,liver fibrosis and other indicators were compared between two groups.Results:HBV-DNA load,serum ALT and AST values as well as HA,LN,C-Ⅳ and PCⅢ values of observation group after the treat-ment were lower than those of control group (P <0.05 );serum TBA and Treg values of observation group after treatment were lower than those of control group,and PAB,CHE,Th1 7 cell and Th1 7/Treg ratio were higher than those of control group (P <0.05).Conclusion:Sequential therapy of interferon and thymosin α1 can optimize the overall condition in patients with nucleoside drugs-resistant hepatitis B cirrhosis,inhibit virus replication and slow down the process of liver fibrosis,and it has positive clinical significance.%目的：：分析干扰素联合胸腺肽α1序贯治疗对耐核苷类药物乙肝肝硬化患者病毒复制及肝纤维化的影响.方法：乙肝肝硬化患者86例作为研究对象,按照随机数表法分为观察组及对照组各43例,对照组接受单独干扰素治疗,观察组接受干扰素联合胸腺肽α1序贯治疗,对比两组病毒复制及肝纤维化等指标差异.结果：观察组治疗后 HBV-DNA 载量,血清 ALT 及 AST 值,HA、LN、C-Ⅳ、PCⅢ值均低于对照组(P ＜0．05)；观察组接受治疗后的血清 TBA、Treg 值低于对照组,PAB、CHE、Th17细胞、Th17/Treg 比值高于对照组(P ＜0．05).结论：干扰素联合胸腺肽α1序贯治疗可以优化耐核苷类药物乙肝肝硬化患者整体病情,在抑制病毒复制的同时减缓肝纤维化进程,具有积极的临床意义.